Impact of Anthracyclines in Genomic High Risk, Node-Negative, HR-Positive/HER2-Negative Breast Cancer
{{output}}
Background: The benefit of anthracyclines for patients with high 21-gene recurrence score (RS) is unclear, despite the widespread use of RS to guide adjuvant chemotherapy treatment for hormone receptor-positive (HR+)/HER2-negativ... ...
